Trovagene, NWU Institutions Partner to Assess Oncogene Mutation Monitoring Tech | GenomeWeb

NEW YORK (GenomeWeb) — Trovagene has entered into a strategic partnership with two Northwestern University institutions to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

Under the alliance, the Robert H. Lurie Comprehensive Care Center and the Northwestern Medicine Developmental Therapeutics Institute will work with Trovagene on clinical protocols that incorporate oncogene mutation monitoring during the course of cancer treatment, and assess their impact on overall disease management and patient outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.